| DCC4236 |
Pradigastat
Featured
|
Pradigastat (LCQ-908) is a potent, selective and orally active diacylglycerol acyltransferase 1 (DGAT1) inhibitor. Pradigastat has anti-obesity and anti-diabetic effects. |
|
| DCC4245 |
Prmt5-in-c17
Featured
|
Novel potent, selective, and cell active protein arginine methyltransferase 5 (PRMT5) inhibitor |
|
| DCC4275 |
Prx-08066 Maleate
Featured
|
Novel potent and selective 5-HT2B receptor antagonist |
|
| DCC4285 |
Psb-1434
Featured
|
Highly potent, selective, competitive, and reversible inhibitor of monoamine oxidase B (MAO-B) |
|
| DCC4286 |
Psb-1491
Featured
|
Highly potent, selective, competitive, and reversible inhibitor of monoamine oxidase B (MAO-B) |
|
| DCC4365 |
Rac-nbi-74330
Featured
|
rac-NBI-74330 is a potent and selective CXCR3 antagonist. |
|
| DCC4502 |
Rs-25344
Featured
|
Selective phosphodiesterase-4 (PDE4) inhibitor |
|
| DCC4810 |
Smu-z1
Featured
|
Novel potent TLR1/2 Specific Agonist, Suppressing Leukemia Cancer Cell Growth by Stimulating Cytotoxic T Lymphocytes |
|
| DCC4907 |
Ssr180575
Featured
|
SSR-180,575 is a drug which acts as a selective agonist at the peripheral benzodiazepine receptor, also known as the mitochondrial 18 kDa translocator protein or TSPO. It has been shown to have neuroprotective and cardioprotective effects and to stimulate steroidogenesis of pregnenolone in the brain, which may be linked to its neuroprotective action. |
|
| DCC4967 |
Sucnr1-in-20
Featured
|
SUCNR1-IN-2 (Statement 35) is a succinate/succinate receptor 1 inhibitor for the study of neurodegenerative diseases such as neuroinflammation. |
|
| DCC4995 |
Szu101
Featured
|
Novel TLR7 agonist via immune response induction and tumor microenvironment modulation |
|
| DCC5054 |
FPR Agonist 43
Featured
|
FPR Agonist 43 (compound 43) is a dual formyl peptide receptor 1 (FPR1) and formyl peptide receptor 2 (FPR2)/ALX agonist. |
|
| DCC5057 |
Tc-i 2000
Featured
|
Novel TRPM8 channel blocker |
|
| DCC5065 |
Tcs2314
Featured
|
Novel Integrin very late antigen-4 (VLA-4; α4β1) antagonist, blocking the activation of inflammatory cells. |
|
| DCC5080 |
Tecovirimat Hydrate
Featured
|
Novel inhibitor of viral p37, blocking the ability of virus particles to be released from infected cells, being used for the treatment of smallpox, monkeypox, orthopoxvirus, and orthopoxviral Disease. |
|
| DCC5082 |
Teijin Compound 1 Hydrochloride
Featured
|
CCR2 antagonist 4 hydrochloride (Teijin compound 1 hydrochloride) is a potent and specific CCR2 antagonist, with IC50s of 180 nM for CCR2b. CCR2 antagonist 4 hydrochloride potently inhibits MCP-1-induced chemotaxis with an IC50 of 24 nM. |
|
| DCC5325 |
Unc0737
Featured
|
UNC0737 is a negative control of UNC0638 and the N-methyl analog of UNC0638. UNC0737 was designed to eliminate the hydrogen bond interaction seen in the G9a-UNC0224 cocrystal structure between Asp1083 of G9a and the secondary amino group at the 4-position of UNC0224's quinazoline ring3. UNC0737 was >300-fold less potent than UNC0638 in G9a and GLP biochemical assays. As expected, UNC0737 was a poor inhibitor of G9a (IC50 = 5,000 ± 200 nM (n = 2)) and GLP (IC50 > 10,000 nM (n = 2)) in the SAHH-coupled assays. |
|
| DCC5343 |
Unipr500
Featured
|
Novel Eph antagonist, inhibiting Eph/ephrin interactions, enhancing glucose-stimulated insulin secretion (GSIS), and acting as a hypoglycemic agent |
|
| DCC5384 |
Vb-201
Featured
|
Novel anticryptosporidial agent, acting as a toll-like receptor-2 (TLR2) antagonist |
|
| DCC5399 |
Ver-246608
Featured
|
Novel pan-isoform ATP competitive inhibitor of pyruvate dehydrogenase kinase, disrupting Warburg metabolism and inducing context-dependent cytostasis in cancer cells |
|
| DCC5423 |
Setmelanotide Tfa Salt
Featured
|
Novel highly-selective melanocortin-4 receptor (MC4R) agonist, increasing resting energy expenditure in obese individuals |
.png)
|
| DCC5447 |
Vu0366248
Featured
|
VU0366248 is a mGlu5 negative allosteric modulator. |
|
| DCC5479 |
Vuf10497
Featured
|
VUF10497 is a potent histamine H4 receptor (H4R) inverse agonist with anti-inflammatory activity. |
|
| DCC5498 |
Biricodar(Vx-710)
Featured
|
Biricodar (VX-710) is a multidrug resistance (MDR) modulator that targets two key drug efflux transporters: P-glycoprotein (Pgp) and multidrug resistance-associated protein 1 (MRP-1). These transporters are often overexpressed in cancer cells and contribute to multidrug resistance (MDR) by pumping chemotherapeutic drugs out of the cells, reducing their intracellular concentration and efficacy. Biricodar inhibits the function of Pgp and MRP-1, effectively chemosensitizing multidrug-resistant cancer cells and enhancing the effectiveness of chemotherapy agents. Its ability to reverse MDR makes it a promising candidate for improving cancer treatment outcomes. |
|
| DCC5500 |
w-13 Hydrochloride
Featured
|
W-13 hydrochloride is a calmodulin antagonist. W-13 hydrochloride can inhibit Tamoxifen (HY-13757A)-resistant human breast cancer cell growth. |
|
| DCC5576 |
Ym-244769
Featured
|
YM-244769 is a potent, selective and orally active Na+/Ca2+ exchanger (NCX) inhibitor. YM-244769 preferentially inhibits NCX3 and suppresses the unidirectional outward NCX current (Ca2+ entry mode), with IC50s of 18 nM and 50 nM, respectively. YM-244769 efficiently protects against hypoxia/reoxygenation-induced SH-SY5Y neuronal cell damage. YM-244769 can also increase urine volume and urinary excretion of electrolytes in mice. |
|
| DCC5670 |
Zxh-1-161
Featured
|
Novel Selective Degrader of GSPT1 |
|
| DC65714 |
Filanesib hydrochloride
Featured
|
Filanesib (ARRY-520) hydrochloride is a selective and noncompetitive kinesin spindle protein (KSP) inhibitor, with an IC50 of 6 nM for human KSP. Filanesib induces cell death by apoptosis in vitro. Filanesib has potent anti-proliferative activity. |
|
| DC65715 |
VU 0364739 hydrochloride
Featured
|
VU0364739 is a selective PLD2 inhibitor (IC50: 22 nM). VU0364739 decreases cancer cell proliferation. |
|
| DC65716 |
RMC6236
Featured
|
RMC-6236 (Compound A122) is a potent RAS(ON)MULTI inhibitor and can be used for the research of cancer. |
|
